RHO and pancreatic neoplasm: However, the treatment with CCG203791 and further second generation Rho/MRTF/SRF pathway inhibitors previously reduced an invasive, migratory and tumorigenic phenotype also in pancreatic cancer [39], osteosarcoma [27] or human colonic myofibroblasts [25], which is in line with the reduced protrusion formation of primary murine and MCF10A-derived acini on stiffer matrices presented here.